New Global Vaccine Action Plan does not go far enough, says MSF

18 May 2012

A new, 10-year, multi-billion dollar action plan for global vaccination may fail to deliver if it does not directly address the weaknesses in routine immunization programs. 19 million children are being missed each year and this challenge must be explicitly addressed, the medical humanitarian organization Medecins Sans Frontieres (MSF) said yesterday.

These comments came as MSF launched a new report, The Right Shot: Extending the Reach of Affordable and Adapted Vaccines, outlining the price and adaptation barriers to reaching more children with life-saving vaccines. To access the report, visit www.msfaccess.org/content/rightshot

A “Global Vaccines Action Plan” has been designed to implement the “Decade of Vaccines” project and will be considered by Health Ministers gathering next week in Geneva, Switzerland, for the 65th World Health Assembly. MSF welcomed the increased emphasis on vaccines stimulated by the Decade of Vaccines but expressed concern that some key challenges are being glossed over.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight



More Features in Pharmaceutical